The following section presents two high-potential Argentine startups operating in strategic biotech sectors — sustainable agriculture and regenerative medicine — that have achieved significant milestones in technology development and are currently in open investment rounds.

APOLO BIOTECH — RNA-based crop protection technology

Sector: AgTech / Biotech / Sustainable Agriculture
Technologies: RNA biology, enzymatic synthesis, bioinformatics, foliar application

APOLO Biotech is an Argentine biotechnology startup developing RNA-based solutions for crop protection and adaptation. Rather than genetically modifying plants, the company develops RNA molecules for foliar application that activate natural plant defences, interfere with pathogen genes, or promote adaptation to biotic and abiotic stress — a sustainable, GMO-free alternative for agriculture. Winner of the SantanderX Global Award (2023) and the World Food Prize Foundation Innovate for Impact Challenge (2025), selected from nearly 400 proposals across 65 countries. Recipient of IDB funding for technology development.

Target investor profile: VC funds and angel investors specialised in AgTech, Biotech, ClimateTech and sustainability; corporate venture capital from agroinput, crop protection, biologicals and agricultural technology companies.

Website: www.apolobiotech.com.ar

VESICLY — Exosome-based regenerative medicine platform

Sector: Biotech / Regenerative Medicine / Life Sciences
Technologies: MSC-derived exosomes, 3D cell culture, lyophilisation, 3D-printable hydrogels

Vesicly is an Argentine biotechnology company developing regenerative medicine solutions based on exosomes derived from mesenchymal stem cells (MSCs). Its proprietary platform combines scalable extracellular vesicle production, stable lyophilised formulations, and controlled delivery via 3D-printable hydrogels — with applications in advanced cosmeceuticals, chronic wound treatment, and biomedical research. Winner of the Draper Grant at the Deep-Tech for Smart Longevity Demo Day (Tecnológico de Monterrey / Draper House Americas). Three letters of intent were signed with cosmetic industry partners.

Target investor profile: VC funds specialised in biotechnology, regenerative medicine, life sciences, and advanced cosmeceuticals; corporate investors from pharma, aesthetic dermatology, wound care, and CDMO sectors.

Website: www.vesicly.com

For further information or to request the full investment decks, please contact the Commercial Section of the Embassy: embargentina_trade@mrecic.gov.ar